Marinus Pharmaceuticals Company Overview

Marinus Pharmaceuticals logo
Marinus Pharmaceuticals
Marinus Pharmaceuticals primary media

About Marinus Pharmaceuticals

Marinus Pharmaceuticals (NASDAQ:MRNS) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of epilepsy and other neuropsychiatric disorders. The company's portfolio is centered around its lead candidate, ganaxolone, which is being explored across multiple studies for its potential in treating a range of seizure disorders and neuropsychiatric conditions. Marinus is committed to advancing neuroscience and aiming to provide new treatment options for patients with unmet medical needs. Through ongoing research and development projects, Marinus strives to expand its understanding of neurological diseases and harness the power of its technology to improve patient outcomes.

What is Marinus Pharmaceuticals known for?

Snapshot

2003
Year founded
172
Employees
Pennsylvania, United States
Head office
Loading Map...

Operations

All Locations
United States

Produtos e/ou serviços de Marinus Pharmaceuticals

  • Ganaxolone for CDKL5 deficiency disorder, a rare form of epilepsy in children.
  • Development of ganaxolone for status epilepticus, severe seizures that do not respond to first-line treatments.
  • Research into ganaxolone for Postpartum Depression, addressing severe mood disorders following childbirth.
  • Investigation of ganaxolone in Tuberous Sclerosis Complex, aiming to reduce seizure frequency in this genetic disorder.
  • Exploration of ganaxolone for treatment-resistant depression, targeting individuals unresponsive to standard therapies.
  • Advancing a proprietary intravenous formulation of ganaxolone for use in hospital settings, enhancing rapid delivery for acute management.

equipe executiva do Marinus Pharmaceuticals

  • Dr. Scott N. Braunstein M.D.CEO, President & Chairman
  • Mr. Steven E. Pfanstiel C.M.A., M.B.A.COO, CFO & Treasurer
  • Dr. Joseph Hulihan M.D.Chief Medical Officer
  • Dr. Alex Aimetti Ph.D.Chief Scientific Officer
  • Ms. Sonya WeigleSenior VP of Investor Relations, Human Resources & Corporate Affairs
  • Ms. Martha E. Manning Esq., J. D.Senior VP, General Counsel & Secretary
  • Molly CameronDirector of Corporate Communications & Investor Relations
  • Dr. Kimberly A. McCormick Pharm.D.Chief Regulatory & Quality Assurance Officer
  • Ms. Christina ShaferChief Commercial Officer
  • Mr. David CzekaiChief Chemistry, Manufacturing & Controls Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.